Clinical trials: Treatment Endometrial Cancer
Endometrial Cancer
BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
This is an open label and single arm study to investigate the safety and efficacy of BEZ235 in adult women with endometrial carcinoma whose disease progressed (or recurred) while on or after first-line antineoplastic treatment…
- Trial name
- NCT01290406
- Testing
- BEZ235
- Where
- 59 sites in United States, Brazil and 10 more
- Sponsor
- Novartis Pharmaceuticals
Myeloma Before MV-NIS Treatment, Endometrial Cancer Before VSV-hINF-NIS Treatment
F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies
The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues. .
- Trial name
- NCT03456908
- Testing
- 18F-TFB-PET
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Breast Cancer
ATAC - Endometrial Sub-Protocol
To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.
- Trial name
- NCT00814125
- Testing
- Anastrozole (Arimidex), Tamoxifen (Nolvadex)
- Volunteers
- 285 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Fallopian Tube Cancer
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
- Trial name
- NCT06906341
- Testing
- Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
- Where
- 49 sites in United States, Belgium and 6 more
- Volunteers
- 270 people
- Sponsor
- Corcept Therapeutics
Endometrium Cancer
Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma
Indoleamine 2,3 dioxygenase 1 (IDO 1) is the major enzyme catabolising the Tryptophan outside the liver. It has been shown that its plays a important role in generating a immunosuppressive micro-environment in tumors.
- Trial name
- CELEBRIDO (NCT03896113)
- Testing
- Celecoxib 200mg capsule
- Where
- 2 sites in Belgium
- Volunteers
- 48 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Solid Tumors
Study of INCB123667 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with…
- Trial name
- NCT05238922
- Testing
- INCB0123667, Palbociclib, Bevacizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 291 people
- Sponsor
- Incyte Corporation
Uterine Cervical Neoplasm, Endometrial Neoplasms
Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
Online adaptive radiotherapy (oART) has demonstrated to be feasible to reduce planning target volume (PTV) margins for postoperative treatment of endometrial and cervical cancer.
- Trial name
- NCT05869123
- Testing
- Online adaptive radiotherapy
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Peking Union Medical College Hospital
Endometrial Cancer, Overweight
the Effectiveness of a Weight Management Program in Patients Who Have Completed Treatment for Endometrial Cancer
The primary purpose of this study is to evaluate the effectiveness of a 12-month comprehensive weight management program on weight change in overweight/obese patients following treatment for endometrial cancer.
- Trial name
- NCT03908996
- Testing
- Profile by Sanford weight management plan
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sanford Health
Cancer-associated Thrombosis, Venous Thromboembolism
The Gynecological Cancer Associated Thrombosis (GynCAT) Study
GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM)…
- Conditions
- Cancer-associated Thrombosis, Venous Thromboembolism, Gynecologic Cancer, Ovarian Cancer
- Trial name
- GynCAT (NCT06284343)
- Testing
- Anticoagulant
- Where
- Italy
- Volunteers
- 1,800 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Endometrial Cancer
Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer
This is a single centre, single arm, open label, preoperative window of opportunity study. Grade 2 endometrioid endometrial carcinoma patients awaiting surgery will be prospectively recruited to receive a pre-operative progestin…
- Trial name
- MA-EEC (NCT05332483)
- Testing
- Megestrol Acetate
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer Female, Breast Neoplasm
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
The purpose of this study is to invite all people diagnosed with cancer who meet the eligibility criteria to complete questionnaires before their treatment begins and at regular intervals over time to assess the impact of cancer…
- Conditions
- Breast Cancer Female, Breast Neoplasm, Non-Hodgkin's B-cell Lymphoma, Non-Hodgkin's Lymphoma, Adult High Grade
- Trial name
- NCT03000192
- Where
- 111 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Endometrial Cancer
Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
Studying adjuvant hypofractionated whole pelvis radiation therapy in Endometrial Cancer.
- Trial name
- NCT04458402
- Testing
- Hypofractionated WPRT
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Teresa Meier
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with recurrent or advanced endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01307631
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic
Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and…
- Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic, Ovarian Cancer, Cervical Carcinoma
- Trial name
- NCT06800612
- Testing
- Oncologic drugs administered for treatment of breast cancer, Oncologic drug administered for treatment of gynecologic cancer
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Carcinosarcoma, Endometrial Neoplasms
Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
The COPELIA trial is evaluating two new tablet medications in endometrial cancer for the first time. It will include 129 women aged 16 years or older with advanced endometrial cancer whose cancer has worsened after their initial…
- Trial name
- COPELIA (NCT03570437)
- Testing
- Paclitaxel, Cediranib, Olaparib
- Where
- 15 sites in United Kingdom
- Volunteers
- 124 people
- Sponsor
- University of Manchester
Solid Tumor, Malignant Lymphoma
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to subjects with advanced solid tumors and recurrent malignant lymphoma.
- Conditions
- Solid Tumor, Malignant Lymphoma, Tumor
- Trial name
- NCT01473095
- Testing
- ARQ 092
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00120939
- Testing
- Motexafin Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
MMRd/MSI-H Stage II-III Endometrial Cancer
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
The study for which participation is requested is a phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial cancer.
- Trial name
- NADIA (NCT07013851)
- Testing
- Dostarlimab
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Endometrial Cancer
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005583
- Testing
- cisplatin, doxorubicin hydrochloride, epirubicin hydrochloride
- Where
- 23 sites in Belgium, France and 9 more
- Volunteers
- 400 people
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Endometrial Cancer, Stage III Endometrial Cancer
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able…
- Conditions
- Endometrial Cancer, Stage III Endometrial Cancer, Stage III Endometrial Carcinoma, Endometrial Carcinoma
- Trial name
- NCT05691010
- Testing
- Intensity-modulated radiation therapy, Carboplatin, Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center